Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

S. sonnei 1790GAHB

Vaccine (Live attenuated vaccine) · Immune activation · developed by GSK Vaccines Institute For Global Health S.r.l.

Phase 1 Most advanced trial (none active)
GSK Developer

What is S. sonnei 1790GAHB?

S. sonnei 1790GAHB is a Shigella sonnei vaccine intended to protect against shigellosis, also known as bacillary dysentery.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine (Live attenuated vaccine)
Mechanism
Immune activation
Therapy area
Infectious disease
Developer
GSK Vaccines Institute For Global Health S.r.l. (GSK)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

Conditions studied

Shigellosis

More from GSK Vaccines Institute For Global Health S.r.l.

Follow GSK, the company behind S. sonnei 1790GAHB

See GSK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GSK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.